Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Squamous Cell Carcinoma of Head and Neck 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Lymphoma 1Lung Neoplasms 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1Gynecological Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × penpulimab × Clear all
NCT07075419 2025-07-20

JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure

West China Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05862337 2023-05-17

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡